Edward J. Ludwig
Edward J. Ludwig's purchase track record
How the stock did after each of Edward J. Ludwig's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/31/2026 | BSX | $227K | pending | pending | — |
| 5/20/2026 | BSX | $203K | -8.2% | pending | — |
| 5/2/2024 | CVS | $54K | +10.1% | +4.7% | +12.7% |
| 11/3/2023 | CVS | $141K | +5.0% | -18.9% | +17.6% |
| 2/10/2022 | CVS | $106K | -6.2% | +0.1% | -6.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status. CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.
Transaction History
| BSX | ▲ Buy | Open Market | 5,000 | $227K | 7/31/2026 | View on chart |
| BSX | ▲ Buy | Open Market | 3,580 | $203K | 5/20/2026 | View on chart |
| BSX | ▲ Buy | Grant | 3,800 | $0 | 5/7/2026 | View on chart |
| BSX | ▼ Sell | Gift | 500 | $0 | 8/1/2025 | View on chart |
| BSX | ▼ Sell | Open Market | 4,000 | $424K | 7/25/2025 | View on chart |
| BSX | ▼ Sell | Open Market | 4,000 | $418K | 5/29/2025 | View on chart |
| BSX | ▲ Buy | Grant | 2,081 | $0 | 5/8/2025 | View on chart |
| BSX | ▼ Sell | Gift | 3,000 | $0 | 2/11/2025 | View on chart |
| BSX | ▼ Sell | Open Market | 12,000 | $1.3M | 2/11/2025 | View on chart |
| BSX | ▼ Sell | Open Market | 4,877 | $447K | 11/21/2024 | View on chart |
| BSX | ▲ Buy | Grant | 2,901 | $0 | 5/9/2024 | View on chart |
| CVS | ▲ Buy | Open Market | 1,000 | $54K | 5/2/2024 | View on chart |
| BSX | ▲ Buy | Option Exercise | 9,818 | $171K | 4/26/2024 | View on chart |
| BSX | ▼ Sell | Open Market | 9,818 | $720K | 4/26/2024 | View on chart |
| BSX | ▲ Buy | Option Exercise | 7,000 | $122K | 2/13/2024 | View on chart |
| BSX | ▼ Sell | Open Market | 7,000 | $455K | 2/13/2024 | View on chart |
| CVS | ▲ Buy | Open Market | 2,000 | $141K | 11/3/2023 | View on chart |
| CVS | ▲ Buy | Grant | 131 | $12K | 11/17/2022 | View on chart |
| CVS | ▲ Buy | Grant | 165 | $16K | 5/11/2022 | View on chart |
| BSX | ▲ Buy | Grant | 4,877 | $0 | 5/5/2022 | View on chart |
| CVS | ▲ Buy | Open Market | 1,000 | $106K | 2/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate
Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.